I read the book and the story is pretty amazing. Scary that Herceptin almost didn't get out of the development phase. One of the take-aways from the book was the power of the advocacy community-- they really rallied to get as many women as possible included in the adjuvent trials, with the well-founded hunch that the drug would be a wonder.
Given the premium that these drugs are commanding, I can imagine that the business development people are all to happy to take bets now on targeted therapy-- at the time Herceptin was developed, it really was out-of-the-box thinking.
Here's a link to the book:
http://www.amazon.com/Her-2-Making-H...8212264&sr=8-1
Jen